Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 14 3 2019
medline: 12 1 2021
entrez: 14 3 2019
Statut: ppublish

Résumé

Many clinical scores for risk stratification in patients with atrial fibrillation have been proposed, and some have been useful in predicting all-cause mortality. We aim to analyse the relationship between clinical risk score and all-cause death occurrence in atrial fibrillation patients. We performed a systematic search in PubMed and Scopus from inception to 22 July 2017. We considered the following scores: ATRIA-Stroke, ATRIA-Bleeding, CHADS Fifty studies and 71 scores groups were included in the analysis, with 669,217 patients. Data on ATRIA-Bleeding, CHADS In atrial fibrillation patients, contemporary clinical risk scores are associated with an increased risk of all-cause death. Use of these scores for death prediction in atrial fibrillation patients could be considered as part of holistic clinical assessment. The CHA

Identifiants

pubmed: 30861693
doi: 10.1177/2047487318817662
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

633-644

Auteurs

Marco Proietti (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Institute of Cardiovascular Sciences, University of Birmingham, UK.

Alessio Farcomeni (A)

Department of Public Health and Infectious Disease, Sapienza-University of Rome, Italy.

Giulio Francesco Romiti (GF)

Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Italy.

Arianna Di Rocco (A)

Department of Public Health and Infectious Disease, Sapienza-University of Rome, Italy.

Filippo Placentino (F)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy.

Igor Diemberger (I)

Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S. Orsola-Malpighi, Italy.

Gregory Yh Lip (GY)

Institute of Cardiovascular Sciences, University of Birmingham, UK.
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Giuseppe Boriani (G)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH